抗菌薬の市場規模、シェア、成長分析、薬剤クラス別、活動スペクトル別、投与経路別、流通チャネル別、地域別 - 産業予測 2025～2032年

抗菌薬の世界市場規模は2023年に486億4,000万米ドルと評価され、2024年の491億8,000万米ドルから2032年には766億7,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.1%で成長する見通しです。

世界の抗菌薬市場は、細菌感染症の増加と抗菌薬耐性（AMR）への懸念が成長の原動力となっています。特に社会的弱者における院内感染の増加が、効果的な治療に対する需要を促進しています。抗菌薬スチュワードシップ・プログラムへの投資と新薬開発のための研究奨励金は、市場を発展させる上で極めて重要です。創薬におけるイノベーションと標的治療薬への注力は、この市場拡大に大きく貢献しています。しかし、市場開発には開発期間の長さやコストの高さなどの課題があり、投資の足かせとなっています。大手製薬会社は、慢性疾患治療に比べて収益性が低いため、抗生物質パイプラインへの投資に消極的です。ヘルスケアや農業での誤用に起因する耐性問題の悪化は、技術革新とアクセシビリティや責任あるスチュワードシップのバランスを取る上で継続的な課題を突きつけています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術分析
• 規制分析
• ケーススタディ分析

抗菌薬市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• アミノグリコシド
• β-ラクタム
  • ペニシリン
  • カルバペネム
  • セファロスポリン
• マクロライド
• フェニコール
• キノロン系/フルオロキノロン系
• スルホンアミド
• テトラサイクリン
• その他の抗菌剤

抗菌薬市場規模：活動スペクトル別& CAGR（2025-2032）

• 市場概要
• 広域スペクトル抗生物質
• 狭域スペクトル抗生物質

抗菌薬市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 静脈内（IV）
• 局所
• 吸入

抗菌薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

抗菌薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Pfizer Inc.
• GlaxoSmithKline plc（GSK）
• Merck & Co., Inc.
• Novartis AG
• Johnson & Johnson
• Sanofi S.A.
• AbbVie Inc.
• Bayer AG
• AstraZeneca plc
• Roche Holding AG
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories
• Mylan N.V.
• Shionogi & Co., Ltd.
• Theravance Biopharma, Inc.

結論と提言

Global Antibacterial Drugs Market size was valued at USD 48.64 Billion in 2023 and is poised to grow from USD 49.18 Billion in 2024 to USD 76.67 Billion by 2032, growing at a CAGR of 6.1% in the forecast period (2025-2032).

The global antibacterial drug market is witnessing growth fueled by rising bacterial infections and concerns over antimicrobial resistance (AMR). Increased hospital-acquired infections, particularly among vulnerable groups, are driving demand for effective treatments. Investment in antimicrobial stewardship programs and research incentives for new drug development are pivotal in advancing the market. Innovations in drug discovery and a focus on targeted therapeutics contribute significantly to this expansion. However, the market faces challenges, including lengthy development timelines and high costs, deterring investment. Major pharmaceutical companies are reluctant to invest in antibiotic pipelines due to lower profitability compared to chronic disease treatments. The worsening resistance issues arising from misuse in healthcare and agriculture pose ongoing challenges for balancing innovation with accessibility and responsible stewardship.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibacterial Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibacterial Drugs Market Segments Analysis

The global Antibacterial Drugs Market is segmented on the basis of drug class, spectrum of activity, route of administration, and distribution channel. By drug class, the market is segmented into aminoglycosides, B-lactams, macrolides

Driver of the Global Antibacterial Drugs Market

The global market for antibacterial drugs is primarily driven by the increasing prevalence of bacterial infections worldwide. With rising incidents of ailments such as pneumonia, tuberculosis, and urinary tract infections, there is a growing need for effective antibacterial treatments. Additionally, the aging demographic, coupled with the escalation of lifestyle-related diseases, further drives the demand for innovative and potent antibiotics to combat resistant bacterial strains. This surge in infection rates and the critical need for advanced therapies highlight the importance of developing new, effective antibacterial medications to ensure comprehensive healthcare solutions.

Restraints in the Global Antibacterial Drugs Market

The Global Antibacterial Drugs market faces significant restraints due to rigorous regulatory requirements that apply, especially to new treatments and formulations. These stringent standards, which include comprehensive clinical trials and safety evaluations, hinder the speed at which products can be approved and brought to market, ultimately restricting growth opportunities. Adhering to both regional and international regulations prolongs the time it takes for new drugs to reach consumers, making it challenging for the industry to effectively meet the increasing demand for antibacterial treatments in a timely manner. Consequently, these factors could impede overall market expansion and innovation.

Market Trends of the Global Antibacterial Drugs Market

The Global Antibacterial Drugs market is witnessing significant growth, propelled by escalating rates of antimicrobial resistance that demand innovative therapeutic solutions. Regulatory agencies and governments worldwide are increasingly prioritizing the development of new treatments to address multidrug-resistant pathogens, thus enhancing R&D investments in this sector. Moreover, the emergence of new bacterial strains, alongside a growing focus on infection control and prevention strategies, is driving demand for advanced antibacterial therapies. This dynamic landscape fosters collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers aimed at discovering and commercializing novel antibacterial agents, thereby reshaping the market's future trajectory.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulation Analysis
• Case Study Analysis

Global Antibacterial Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Aminoglycosides
• B-Lactams
  • Penicillin
  • Carbapenem
  • Cephalosporin
• Macrolides
• Phenicols
• Quinolones/Fluoroquinolones
• Sulfonamides
• Tetracyclines
• Other Antibacterials

Global Antibacterial Drugs Market Size by Spectrum of Activity & CAGR (2025-2032)

• Market Overview
• Broad-spectrum antibiotics
• Narrow-spectrum antibiotics

Global Antibacterial Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous (IV)
• Topical
• Inhalation

Global Antibacterial Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Antibacterial Drugs Market Size & CAGR (2025-2032)

• North America (Drug Class, Spectrum of Activity, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Spectrum of Activity, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Spectrum of Activity, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Spectrum of Activity, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Spectrum of Activity, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theravance Biopharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations